Fulgent Genetics (FLGT) Accounts Payables (2015 - 2026)

Fulgent Genetics (FLGT) has 12 years of Accounts Payables data on file, last reported at $21.1 million in Q1 2026.

• Quarterly Accounts Payables rose 15.83% year-over-year to $21.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $21.1 million (up 15.83% YoY) and the FY2025 annual result came in at $18.7 million, up 1.58% from the prior year.
• Accounts Payables advanced to $21.1 million in Q1 2026 per FLGT's latest filing, from $18.7 million in the prior quarter.
• The five-year high for Accounts Payables was $37.1 million in Q2 2022, with the low at $14.5 million in Q3 2022.
• Average Accounts Payables over 5 years is $20.3 million, with a median of $19.6 million recorded in 2024.
• Year-over-year, Accounts Payables jumped 151.71% in 2022 and tumbled 44.47% in 2023.
• Fulgent Genetics' Accounts Payables stood at $23.1 million in 2022, then sank by 33.49% to $15.4 million in 2023, then increased by 19.56% to $18.4 million in 2024, then climbed by 1.58% to $18.7 million in 2025, then rose by 13.25% to $21.1 million in 2026.
• Business Quant data shows FLGT's Accounts Payables at $21.1 million in Q1 2026, $18.7 million in Q4 2025, and $18.1 million in Q3 2025.